California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.
We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...
The global CDMO has entered into several high-value manufacturing deals this year. The global contract development and manufacturing organization (CDMO), Samsung Biologics, announced this week that it ...
From discovering her knack for chemistry in high school to proving her expertise in male-dominated spaces, Tran Pham has built a dynamic career in biopharma. Now the Global market development manager ...
The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the chronic skin condition. The phase 3 ICONIC-LEAD study showed that icotrokinra, ...
From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of resilience and curiosity. Now leading the Biopharma product management team at ...
Stefan Glombitza has over 28 years of experience in the pharmaceutical business, having long worked in the generics space before joining Formycon as Chief Operating Officer in 2016 and being appointed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback